Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.

NACompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Osteoarthritis, Knee
Interventions
DEVICE

ENKO 1

50 mg of HA/ 50 mg of CS in 5 ml

DEVICE

Durolane

60 mg HA crosslinked in 3 ml

Trial Locations (18)

11139

Clínica Novo Sancti Petri, Chiclana de la Frontera

15009

Instituto Médico Arriaza, A Coruña

28002

Clínica IQTRA, Torrejón de Ardoz

28027

BiClinic, Madrid

28250

Hospital de Torrelodones, Torrelodones

29004

AMS Centro Médico del Ejercicio, Málaga

29651

Clínica Dr. Casermeiro, Mijas Costa

41001

Clínica ISMEC, Seville

46015

Clínica Gastaldi, Valencia

47004

Clínica Traumatológica Dr. Baró, Valladolid

08950

Clínica Diagonal, Esplugues de Llobregat

Consell calatà de l'Esport, Esplugues de Llobregat

08227

Consorci Sanitari de Terrassa, Terrassa

08003

Hospital del Mar, Barcelona

08022

Instituto POAL del Reumatología, Barcelona

08035

Hospital Sant Rafael, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

01008

Hospital Vithas San José, Vitoria-Gasteiz

All Listed Sponsors
collaborator

Osteoarthritis Foundation International (OAFI)

UNKNOWN

lead

OPKO Health, Inc.

INDUSTRY

NCT03762408 - Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis. | Biotech Hunter | Biotech Hunter